A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated-glycoconjugates

Immunobiology

Volumn 216, Issue 12, 2011, Pages 1239-1247

  Fernández Marrero, Yuniel ^a   Roque Navarro, Lourdes ^a   Hernández, Tays ^a   Dorvignit, Denise ^a   Molina Pérez, Marively ^b   González, Addys ^a   Sosa, Katya ^a   López Requena, Alejandro ^a   Pérez, Rolando ^a   Mateo de Acosta, Cristina ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b Criminality Central Laboratory   (Cuba)

Author keywords

Cmah; Cytotoxic antibody; Gangliosides; Humanization; N glycolyl GM3; ShRNA

Indexed keywords

ANTINEOPLASTIC AGENT; CHIMERIC PROTEIN; EPITOPE; GANGLIOSIDE ANTIBODY; GLYCOCONJUGATE; GLYCOLYTIC ENZYME; MONOCLONAL ANTIBODY 14F7; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; GENE; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; HUMANIZED 14F7 GENE; IMMUNOCYTOTOXICITY; LEUKEMIA L 1210; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCALE UP; SYNTHESIS; T LYMPHOCYTE;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; FEMALE; G(M3) GANGLIOSIDE; HUMANS; HYBRIDOMAS; IMMUNOTHERAPY; MICE; MIXED FUNCTION OXYGENASES; MOLECULAR TARGETED THERAPY; MUTAGENESIS, SITE-DIRECTED; PROTEIN ENGINEERING; RNA, SMALL INTERFERING;

EID: 80054944831     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2011.07.004     Document Type: Article

References (66)

1. Aixinjueluo W., Furukawa K., Zhang Q., Hamamura K., Tokuda N., Yoshida S., Ueda R. Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis. J. Biol. Chem. 2005, 280(33):29828-29836.
2. Alfonso M., Vazquez A.M., Carr A., Haerslev T., Fernandez L.E., Lanio M.E., Alvarez C., Zeuthen J., Perez R. T cell-independent B cell response to self-monosialogangliosides: primary response monoclonal antibodies. Hybridoma 1995, 14(3):209-216.
3. Almagro J.C., Fransson J. Humanization of antibodies. Front. Biosci. 2008, 13:1619-1633.
4. Barbour S., Edidin M., Felding-Habermann B., Taylor-Norton J., Radin N.S., Fenderson B.A. Glycolipid depletion using a ceramide analogue (PDMP) alters growth, adhesion, and membrane lipid organization in human A431 cells. J. Cell. Physiol. 1992, 150(3):610-619.
5. Bardor M., Nguyen D.H., Diaz S., Varki A. Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J. Biol. Chem. 2005, 280(6):4228-4237.
6. Becker E., Florin L., Pfizenmaier K., Kaufmann H. Evaluation of a combinatorial cell engineering approach to overcome apoptotic effects in XBP-1(s) expressing cells. J. Biotechnol. 2010, 146(4):198-206.
7. Carr A., Mesa C., del Carmen Arango M., Vazquez A.M., Fernandez L.E. In vivo and in vitro anti-tumor effect of 14F7 monoclonal antibody. Hybrid. Hybridomics 2002, 21(6):463-468.
8. Carr A., Mullet A., Mazorra Z., Vazquez A.M., Alfonso M., Mesa C., Rengifo E., Perez R., Fernandez L.E. A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 2000, 19(3):241-247.
9. Carr A., Rodriguez E., Arango Mdel C., Camacho R., Osorio M., Gabri M., Carrillo G., Valdes Z., Bebelagua Y., Perez R., Fernandez L.E. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J. Clin. Oncol. 2003, 21(6):1015-1021.
10. Coloma M.J., Hastings A., Wims L.A., Morrison S.L. Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J. Immunol. Methods 1992, 152(1):89-104.
11. Chou H.H., Takematsu H., Diaz S., Iber J., Nickerson E., Wright K.L., Muchmore E.A., Nelson D.L., Warren S.T., Varki A. A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc. Natl. Acad. Sci. U.S.A. 1998, 95(20):11751-11756.
12. de Leon J., Fernandez A., Clavell M., Labrada M., Bebelagua Y., Mesa C., Fernandez L.E. Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25- effector and naturally occurring CD4+CD25+ regulatory T cells function. Int. Immunol. 2008, 20(4):591-600.
13. de Leon J., Fernandez A., Mesa C., Clavel M., Fernandez L.E. Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol. Immunother. 2006, 55(4):443-450.
14. Doolan P., Meleady P., Barron N., Henry M., Gallagher R., Gammell P., Melville M., Sinacore M., McCarthy K., Leonard M., Charlebois T., Clynes M. Microarray and proteomics expression profiling identifies several candidates, including the valosin-containing protein (VCP), involved in regulating high cellular growth rate in production CHO cell lines. Biotechnol. Bioeng. 2010, 106(1):42-56.
15. Ghaderi D., Taylor R.E., Padler-Karavani V., Diaz S., Varki A. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat. Biotechnol. 2010, 28(8):863-867.
16. Green L.L. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J. Immunol. Methods 1999, 231(1-2):11-23.
17. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 1996, 56(23):5309-5318.
18. Horwacik I. Gangliosides as carbohydrate antigens associated with cancer and their possible use in tumor immunotherapy. Przegl. Lek. 2004, 61(Suppl. 2):14-19.
19. Hwang W.Y., Foote J. Immunogenicity of engineered antibodies. Methods 2005, 36(1):3-10.
20. Ibarra N., Watanabe S., Bi J.X., Shuttleworth J., Al-Rubeai M. Modulation of cell cycle for enhancement of antibody productivity in perfusion culture of NS0 cells. Biotechnol. Prog. 2003, 19(1):224-228.
21. Irie A., Koyama S., Kozutsumi Y., Kawasaki T., Suzuki A. The molecular basis for the absence of N-glycolylneuraminic acid in humans. J. Biol. Chem. 1998, 273(25):15866-15871.
22. Kabat E., Wu T., Perry H., Gottesmann K., Foeller C. Sequences of Proteins of Immunological Interest 1991, Department of Health and Human Service, U.S. Government Printing Office.
23. Kammann M., Laufs J., Schell J., Gronenborn B. Rapid insertional mutagenesis of DNA by polymerase chain reaction (PCR). Nucleic Acids Res. 1989, 17(13):5404.
24. Kannagi R., Yin J., Miyazaki K., Izawa M. Current relevance of incomplete synthesis and neo-synthesis for cancer-associated alteration of carbohydrate determinants - Hakomori's concepts revisited. Biochim. Biophys. Acta 2008, 1780(3):525-531.
25. Kawano T., Kozutsumi Y., Kawasaki T., Suzuki A. Biosynthesis of N-glycolylneuraminic acid-containing glycoconjugates. Purification and characterization of the key enzyme of the cytidine monophospho-N-acetylneuraminic acid hydroxylation system. J. Biol. Chem. 1994, 269(12):9024-9029.
26. Kenten J.H., Molgaard H.V., Houghton M., Derbyshire R.B., Viney J., Bell L.O., Gould H.J. Cloning and sequence determination of the gene for the human immunoglobulin epsilon chain expressed in a myeloma cell line. Proc. Natl. Acad. Sci. U.S.A. 1982, 79(21):6661-6665.
27. Kohler H., Shimizu A., Paul C., Moore V., Putnam F.W. Three variable-gene pools common to IgM, IgG and IgA immunoglobulins. Nature 1970, 227(5265):1318-1320.
28. Kramer O., Klausing S., Noll T. Methods in mammalian cell line engineering: from random mutagenesis to sequence-specific approaches. Appl. Microbiol. Biotechnol. 2010, 88(2):425-436.
29. Krengel U., Olsson L.L., Martinez C., Talavera A., Rojas G., Mier E., Angstrom J., Moreno E. Structure and molecular interactions of a unique antitumor antibody specific for N-glycolyl GM3. J. Biol. Chem. 2004, 279(7):5597-5603.
30. Lasunskaia E.B., Fridlianskaia I.I., Darieva Z.A., da Silva M.S., Kanashiro M.M., Margulis B.A. Transfection of NS0 myeloma fusion partner cells with HSP70 gene results in higher hybridoma yield by improving cellular resistance to apoptosis. Biotechnol. Bioeng. 2003, 81(4):496-504.
31. Liu X.Y., Pop L.M., Vitetta E.S. Engineering therapeutic monoclonal antibodies. Immunol. Rev. 2008, 222:9-27.
32. Lopez-Requena A., Mateo de Acosta C., Perez A., Valle A., Lombardero J., Sosa K., Perez R., Vazquez A.M. Chimeric anti-N-glycolyl-ganglioside and its anti-idiotypic MAbs: immunodominance of their variable regions. Hybrid. Hybridomics 2003, 22(4):235-243.
33. Malykh Y.N., Schauer R., Shaw L. N-glycolylneuraminic acid in human tumours. Biochimie 2001, 83(7):623-634.
34. Margalit H., Spouge J.L., Cornette J.L., Cease K.B., Delisi C., Berzofsky J.A. Prediction of immunodominant helper T cell antigenic sites from the primary sequence. J. Immunol. 1987, 138(7):2213-2229.
35. Marquina G., Waki H., Fernandez L.E., Kon K., Carr A., Valiente O., Perez R., Ando S. Gangliosides expressed in human breast cancer. Cancer Res. 1996, 56(22):5165-5171.
36. Mateo C., Lombardero J., Moreno E., Morales A., Bombino G., Coloma J., Wims L., Morrison S.L., Perez R. Removal of amphipathic epitopes from genetically engineered antibodies: production of modified immunoglobulins with reduced immunogenicity. Hybridoma 2000, 19(6):463-471.
37. Mateo C., Moreno E., Amour K., Lombardero J., Harris W., Perez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997, 3(1):71-81.
38. Morris M.J., Pandit-Taskar N., Divgi C.R., Bender S., O'Donoghue J.A., Nacca A., Smith-Jones P., Schwartz L., Slovin S., Finn R., Larson S., Scher H.I. Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin. Cancer Res. 2007, 13(9):2707-2713.
39. Morrison S.L., Johnson M.J., Herzenberg L.A., Oi V.T. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. U.S.A. 1984, 81(21):6851-6855.
40. Mulens V., de la Torre A., Marinello P., Rodriguez R., Cardoso J., Diaz R., O'Farrill M., Macias A., Viada C., Saurez G., Carr A., Crombet T., Mazorra Z., Perez R., Fernandez L.E. Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: results from a controlled study in metastatic breast cancer patients. Hum. Vaccin. 2010, 6(9).
41. Nanus D.M., Milowsky M.I., Kostakoglu L., Smith-Jones P.M., Vallabahajosula S., Goldsmith S.J., Bander N.H. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J. Urol. 2003, 170(6 Pt 2):S84-S88. (discussion S88-89).
42. Nguyen D.H., Tangvoranuntakul P., Varki A. Effects of natural human antibodies against a nonhuman sialic acid that metabolically incorporates into activated and malignant immune cells. J. Immunol. 2005, 175(1):228-236.
43. Oliva J.P., Valdes Z., Casaco A., Pimentel G., Gonzalez J., Alvarez I., Osorio M., Velazco M., Figueroa M., Ortiz R., Escobar X., Orozco M., Cruz J., Franco S., Diaz M., Roque L., Carr A., Vazquez A.M., Mateos C., Rubio M.C., Perez R., Fernandez L.E. Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc. Breast Cancer Res. Treat. 2006, 96(2):115-121.
44. Padler-Karavani V., Yu H., Cao H., Chokhawala H., Karp F., Varki N., Chen X., Varki A. Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology 2008, 18(10):818-830.
45. Pattingre S., Bauvy C., Levade T., Levine B., Codogno P. Ceramide-induced autophagy: to junk or to protect cells?. Autophagy 2009, 5(4):558-560.
46. Potapenko M., Shurin G.V., de Leon J. Gangliosides as immunomodulators. Adv. Exp. Med. Biol. 2007, 601:195-203.
47. Retter M.W., Johnson J.C., Peckham D.W., Bannink J.E., Bangur C.S., Dresser K., Cai F., Foy T.M., Fanger N.A., Fanger G.R., Woda B., Rock K.L. Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts. Cancer Res. 2005, 65(14):6425-6434.
48. Riechmann L., Clark M., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature 1988, 332(6162):323-327.
49. Rodriguez M., Llanes L., Perez A., Perez R., Vazquez A.M. Generation and characterization of an anti-idiotype monoclonal antibody related to GM3(NeuGc) ganglioside. Hybrid. Hybridomics 2003, 22(5):307-314.
50. Rodriguez M., Roque-Navarro L., Lopez-Requena A., Moreno E., Mateo de Acosta C., Perez R., Maria Vazquez A. Insights into the immunogenetic basis of two ganglioside-associated idiotypic networks. Immunobiology 2007, 212(1):57-70.
51. Rojas G., Talavera A., Munoz Y., Rengifo E., Krengel U., Angstrom J., Gavilondo J., Moreno E. Light-chain shuffling results in successful phage display selection of functional prokaryotic-expressed antibody fragments to N-glycolyl GM3 ganglioside. J. Immunol. Methods 2004, 293(1-2):71-83.
52. Roque-Navarro L., Chakrabandhu K., de Leon J., Rodriguez S., Toledo C., Carr A., de Acosta C.M., Hueber A.O., Perez R. Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol. Cancer Ther. 2008, 7(7):2033-2041.
53. Roque-Navarro L., Mateo C., Lombardero J., Mustelier G., Fernandez A., Sosa K., Morrison S.L., Perez R. Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method. Hybrid. Hybridomics 2003, 22(4):245-257.
54. Studnicka G.M., Soares S., Better M., Williams R.E., Nadell R., Horwitz A.H. Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues. Protein Eng. 1994, 7(6):805-814.
55. Stults C.L., Sweeley C.C., Macher B.A. Glycosphingolipids: structure, biological source, and properties. Methods Enzymol. 1989, 179:167-214.
56. Tangvoranuntakul P., Gagneux P., Diaz S., Bardor M., Varki N., Varki A., Muchmore E. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc. Natl. Acad. Sci. U.S.A. 2003, 100(21):12045-12050.
57. Taylor R.E., Gregg C.J., Padler-Karavani V., Ghaderi D., Yu H., Huang S., Sorensen R.U., Chen X., Inostroza J., Nizet V., Varki A. Novel mechanism for the generation of human xeno-autoantibodies against the nonhuman sialic acid N-glycolylneuraminic acid. J. Exp. Med. 2010, 207(8):1637-1646.
58. Tempest P.R., Bremner P., Lambert M., Taylor G., Furze J.M., Carr F.J., Harris W.J. Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo. Biotechnology (N.Y.) 1991, 9(3):266-271.
59. Vazquez A.M., Alfonso M., Lanne B., Karlsson K.A., Carr A., Barroso O., Fernandez L.E., Rengifo E., Lanio M.E., Alvarez C., et al. Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids. Hybridoma 1995, 14(6):551-556.
60. Vazquez A.M., Perez A., Hernandez A.M., Macias A., Alfonso M., Bombino G., Perez R. Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody. Hybridoma 1998, 17(6):527-534.
61. Vazquez A.M., Tormo B., Velandia A., Giscombe R., Ansotegui I., Jeddi-Tehrani M., Perez R., Mellstedt H., Biberfeld P. Characterization of the colorectal antigen IOR-C2. Hybridoma 1992, 11(2):245-256.
62. Wright A., Shin S.U., Morrison S.L. Genetically engineered antibodies: progress and prospects. Crit. Rev. Immunol. 1992, 12(3-4):125-168.
63. Wu H., Nie Y., Huse W.D., Watkins J.D. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. J. Mol. Biol. 1999, 294(1):151-162.
64. Wu S.C. RNA interference technology to improve recombinant protein production in Chinese hamster ovary cells. Biotechnol. Adv. 2009, 27(4):417-422.
65. Zafir-Lavie I., Michaeli Y., Reiter Y. Novel antibodies as anticancer agents. Oncogene 2007, 26(25):3714-3733.
66. Zhou Q., Shankara S., Roy A., Qiu H., Estes S., McVie-Wylie A., Culm-Merdek K., Park A., Pan C., Edmunds T. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol. Bioeng. 2008, 99(3):652-665.